NTLA - Intellia Therapeutics, Inc

NTLA

$11.96 0.63 (-4.97%) Last updated: Oct 13, 2026 18:09

52-Week Range

$11.96

$7.95 $11.96 $28.25

Fundamentals Overview

Intellia Therapeutics, Inc is near the low of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/B 3.25 P/S 29.89

Risk (Beta)

1.84 — higher vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 64% confidence Risk: High Volatility — Beta 1.84. Consider smaller position size due to higher beta.

Pressures (Sell):

P/S 29.89 (elevated) · Beta 1.84 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$1.76B

P/E (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

52-Week Range

$7.95 - $28.25

Volume vs Avg

0.54x

54% of avg (Below)

Beta

1.84

About

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies t...

Sector: Healthcare

Headquarters: US

Website: www.intelliatx.com

Beta: 1.84 (More volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	N/A
PEG (TTM)	N/A
P/B (TTM)	3.25
P/S (TTM)	29.89
Profitability
ROE (TTM)	-57.79%
ROA (TTM)	-47.29%
Revenue growth (YoY)	N/A
Net margin (TTM)	-672.16%
Operating margin (TTM)	-711.66%
Debt to equity (TTM)	0

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for NTLA.

Loading analyst coverage...

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.